PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(РС	CT Artcle 36 and Rule 70)	STATE TO THE PARTY OF THE PARTY				
Applicant's or agent's file reference OPP043595KR FOR FURT	HER ACTION	See Form PCT/IPEA/416				
T	ling date(day/month/year) IBER 2004 (29.12.2004)	Priority date (day/month/year) 31 DECEMBER 2003 (31.12.2003)				
International Patent Classification (IPC) or national class						
C12P 17/02(2006.01)i						
Applicant	V = 14.					
SAMYANG GENEX CORPORATION et	al					
This report is the international preliminary examin Authority under Article 35 and transmitted to the state.						
2. This REPORT consists of a total of4	sheets, including this cover	sheet.				
3. This report is also accompanied by ANNEXES, c a. (sent to the applicant and to the Internation		sheets, as follows:				
sheets of the description, claims a	and/or drawings which have be	en amended and are the basis for this report				
and/or sheets containing rectificat Administrative Instructions).	ions authorized by this Authori	ty (see Rule 70.16 and Section 607 of the				
	eets, but which this Authority c	onsiders contain an amendment that goes				
beyond the disclosure in the inten Supplemental Box.	national application as filed, as	indicated in item 4 of Box No. I and the				
b. (sent to the International Bureau only) a	es related thereto, in electronic	form only, as indicated in the Supplemental				
4. This report contains indications relating to the foll	laning items:					
Box No. I Basis of the report	ownig terms.					
Box No. II Priority						
Box No. III Non-establishment of opinion	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability					
Box No. IV Lack of unity of invention	Box No. IV Lack of unity of invention					
Box No. V Reasoned statement under citations and explanations s	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement					
Box No. VI Certain documents cited						
Box No. VII Certain defects in the intern	Box No. VII Certain defects in the international application					
Box No. VIII Certain observations on the international application						
Date of submission of the demand	Date of completion	of this report				
28 JULY 2005 (28.07.2005)	17 APRIL	2006 (17.04.2006)				
Name and mailing address of the IPEA/KR	Authorized officer	Annual				
Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-70 Republic of Korea)1, SEONG, You	ing Hwan				
Facsimile No. 82-42-472-7140	Telephone No. 82	-42-481-5975				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/KR2004/003491

Bo	x No.	Basis of the report
1.		regard to the language, this report is based on the international application in the language in which it was filed, unless rwise indicated under this item. This report is based on translations from the original language into the following language
2.	to the	regard to the elements of the international application, this report is based on (replacement sheets which have been furnished receiving Office in response to an invitation under Article 14 are referred to in this reort as "originally filed" and are not sed to this report): the international application as originally filed/furnished the description:
		pages as originally filed/furnished
		pages* received by this Authority on
		pages* received by this Authority on
		r-u
		the claims:
		pagesas originally filed/furnished
		pages* as amended (together with any statment) under Article 19
		pages* received by this Authority on
		pages* received by this Authority on
	_	
	\sqcup	the drawings:
		pagesas originally filed/furnished
		pages* received by this Authority on
		pages*received by this Authority on
3.		the sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing. The amendments have resulted in the cancellation of: the description, pages the claims, Nos. the drawings, sheets the sequence listing (specify): any table(s) related to sequence listing (specify):
4.		This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).
·	If iten	4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/KR2004/003491

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement			•
Novelty (N)	Claims	1 - 12	YES
	Claims	None :	NO
Inventive step (IS)	Claims	1 - 12	YES
• • •	Claims	None	NO
Industrial applicability (IA)	Claims	1 - 12	YES
	Claims	None	NO

2. Citations and explanations (Rule 70.7)

The following documents have been considered for the purpose of this written opinion:

01: The Plant Cell, Vol. 15: 1468-1479 (2003-06)

D2: WO 1989/06686 (1989-07-27) 🗸

1. Novelty and Inventive Step

The present invention relates to a method for mass production of secondary metabolites by culturing plant cells in a medium treated with alkanoic acid or its salt, and a medium for producing secondary metabolites in plant cell culture comprising plant cell culture medium and o.1mM to 20mM of alkanoic acid or its salt.

D1 is provided to produce first metabolites by enhancing the expression of a specific protein, wherein transgenic tobacco plants containing P-GUS are treated with sodium butyrate at 5 to 50mM, which are inhibitors of HDA, to increase the acetylation of the histones present on the PetE promoter.

D2 discloses a process to enhance the efficiency of specific protein production by adding an effective amount of butyric acid or its salt to the culture medium. Specifically, the production of monoclonal antibodies is enhanced by culturing hybridoma cells in a medium containing an effective amount of butyric acid.

The subject matter of claims 1 to 9 is a method for production of secondary metabolites by culturing plant cells in a medium containing alkanoic acid or its salt.

Compared with the present application, none of the above-mentioned prior art documents suggests a method for production of secondary metabolites in plant cell culture by treating a culture medium with alkanoic acid or salt thereof.

The subject matter of claims 10 to 12 is a medium for producing secondary metabolites in plant cell culture comprising plant cell culture medium and o.1mM to 20mM of alkanoic acid or its salt.

(Continued on Supplemental Sheet.)

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/KR2004/003491

Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Box. V

Compared with the present application, none of the above-mentioned prior art documents suggest a medium producing secondary metabolites containing alkanoic acid or its salt for plant cell culture.

In addition, concerning the effect in mass production of secondary metabolites in plant cell culture by enhancing secondary metabolism of plant cells with treatment of a culture medium with alkanoic acid or salt thereof, the present invention is remarkable over D1 and D2.

Therefore, the subject matter of claims 1 to 12 of the present invention does not seem to be easily invented by a person skilled in the art by using the teachings of D1 for enhancing the expression of a specific protein and D2 for enhancing the efficiency of specific protein production.

Accordingly, the subject matter of claims 1 to 12 is novel and also involves an inventive step [PCT Article 33(2) and (3)].

2. Industrial Applicability

The present invention relates to a method for mass production of industrially applicable secondary metabolites by culturing plant cells and a culturing medium thereof.

Therefore, the subject matter of claims 1-12 is considered to be industrially applicable [PCT Article 33(4)].